STTK

Shattuck Labs, Inc.

Healthcare
Biotechnology
$560M market cap

Forecast run · Sep 14, 2026Upside rank 381 of 3,136

Model Signal

ForecastQ Daily Probabilities

59.1%

34.9%

35.9%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$6.20

Price target$13.20

Implied move+112.9%

Analysts9

ForecastQ Portfolios

STTK is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.